Patents by Inventor Naomi Kitamoto
Naomi Kitamoto has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230242529Abstract: One of the purposes of the present invention is to provide a heterocyclic derivative that has an IAP (particularly XIAP) binding (inhibiting) activity. Another of the purposes of the present invention is to provide a heterocyclic derivative that has an IAP (particularly XIAP) binding (inhibiting) activity and exhibits a protein degradation induction activity. The present invention provides a compound represented by formula (I) (the symbols in the formula are as defined in the present Description) and salts thereof.Type: ApplicationFiled: February 16, 2023Publication date: August 3, 2023Applicant: FIMECS, Inc.Inventors: Yusuke TOMINARI, Yoshihide TOMATA, Kanae GAMO, Naomi KITAMOTO
-
Patent number: 11639354Abstract: One of the purposes of the present invention is to provide a heterocyclic derivative that has an IAP (particularly XIAP) binding (inhibiting) activity. Another of the purposes of the present invention is to provide a heterocyclic derivative that has an IAP (particularly XIAP) binding (inhibiting) activity and exhibits a protein degradation induction activity. The present invention provides a compound represented by formula (I) (the symbols in the formula are as defined in the present Description) and salts thereof.Type: GrantFiled: July 31, 2019Date of Patent: May 2, 2023Assignee: FIMECS, INC.Inventors: Yusuke Tominari, Yoshihide Tomata, Kanae Gamo, Naomi Kitamoto
-
Publication number: 20220402935Abstract: It is to provide a novel heterocyclic compound which has the effect of inducing degradation of interleukin-1 receptor-associated kinase-M (IRAK-M) protein and is expected to be useful for the prevention/treatment of cancer, fibrosis, infectious diseases, etc. The present invention provides a compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: July 31, 2020Publication date: December 22, 2022Applicant: FIMECS, INC.Inventors: Yusuke TOMINARI, Yoshihide TOMATA, Kanae GAMO, Naomi KITAMOTO
-
Publication number: 20220378024Abstract: A genetically modified non-human animal in which an auxin-inducible degron system controls degradation of a target protein in a living body includes: a chromosome containing a first nucleic acid that encodes a mutant TIR1 family protein having a mutation at an auxin-binding site and having affinity to an auxin analog.Type: ApplicationFiled: April 30, 2020Publication date: December 1, 2022Inventors: Masato KANEMAKI, Ken-ichiro HAYASHI, Naomi KITAMOTO, Yumiko SAGA, Rieko AJIMA
-
Publication number: 20210179614Abstract: One of the purposes of the present invention is to provide a heterocyclic derivative that has an IAP (particularly XIAP) binding (inhibiting) activity. Another of the purposes of the present invention is to provide a heterocyclic derivative that has an IAP (particularly XIAP) binding (inhibiting) activity and exhibits a protein degradation induction activity. The present invention provides a compound represented by formula (I) (the symbols in the formula are as defined in the present Description) and salts thereof.Type: ApplicationFiled: July 31, 2019Publication date: June 17, 2021Applicant: FIMECS, INC.Inventors: Yusuke TOMINARI, Yoshihide TOMATA, Kanae GAMO, Naomi KITAMOTO
-
Patent number: 10738004Abstract: Provided is a compound, such as ethyl 6-((2-chloro-4-fluorobenzyl)sulfonyl) -3-hydroxycyclohex-1-ene-1-carboxylate or an optical isomer thereof, having a superior Toll-like receptor 4 (TLR4) signaling inhibitory action, which may be useful as a prophylactic or therapeutic drug for diseases such as autoimmune diseases and/or inflammatory diseases, or chemotherapy-induced peripheral neuropathy (CIPN), chemotherapy-induced neuropathic pain (CINP), liver failure, and ischemia reperfusion injury (IRI).Type: GrantFiled: September 7, 2017Date of Patent: August 11, 2020Assignee: Takeda Pharmaceutical Company LimitedInventors: Toshitake Kobayashi, Morihisa Saitoh, Yasufumi Wada, Nobuyuki Negoro, Masashi Yamasaki, Takahiro Tanaka, Naomi Kitamoto
-
Publication number: 20190233370Abstract: The present invention provides a compound having a superior Toll-like receptor 4 (TLR4) signaling inhibitory action, which may be useful as a prophylactic or therapeutic drug for diseases such as autoimmune diseases and/or inflammatory diseases, or chemotherapy-induced peripheral neuropathy (CIPN), chemotherapy-induced neuropathic pain (CINP), liver failure, and ischemia reperfusion injury (IRI). The present invention relates to ethyl 6-((2-chloro-4-fluorobenzyl)sulfonyl)-3-hydroxycyclohex-1-ene-1-carboxylate or an optical isomer thereof.Type: ApplicationFiled: September 7, 2017Publication date: August 1, 2019Applicant: Takeda Pharmaceutical Company LimitedInventors: Toshitake KOBAYASHI, Morihisa SAITOH, Yasufumi WADA, Nobuyuki NEGORO, Masashi YAMASAKI, Takahiro TANAKA, Naomi KITAMOTO
-
Publication number: 20180118708Abstract: The present invention provides compounds having a Toll-like receptor 4 (TLR4) signaling inhibitory action useful as preventive and therapeutic drugs of autoimmune disease and/or inflammatory disease or diseases such as chemotherapy-induced peripheral neuropathy (CIPN), chemotherapy-induced neuropathic pain (CINP), liver injury, ischemia-reperfusion injury (IRI) and the like. The present invention relates to a compound represented by formula (I) and a salt thereof: (wherein, each symbol is explained in greater detail in the specification).Type: ApplicationFiled: May 6, 2016Publication date: May 3, 2018Applicant: Takeda Pharmaceutical Company LimitedInventors: Toshitake KOBAYASHI, Morihisa SAITOH, Yasufumi WADA, Hiroshi NARA, Nobuyuki NEGORO, Masashi YAMASAKI, Takahiro TANAKA, Naomi KITAMOTO
-
Patent number: 9828357Abstract: The present invention provides compounds having a Toll-like receptor 4 (TLR4) signaling inhibitory action useful as preventive and therapeutic drugs of inflammatory disease and/or central nervous system disease or diseases such as chemotherapy-induced peripheral neuropathy (CIPN), chemotherapy-induced neuropathic pain (CINP), liver injury, ischemia-reperfusion injury (IRI) and the like. The present invention relates to a compound represented by formula (I) and a salt thereof: wherein, each symbol is explained in greater detail in the specification.Type: GrantFiled: November 21, 2016Date of Patent: November 28, 2017Assignee: Takeda Pharmaceutical Company LimitedInventors: Toshitake Kobayashi, Morihisa Saitoh, Yasufumi Wada, Hiroshi Nara, Nobuyuki Negoro, Taisuke Katoh, Masashi Yamasaki, Takahiro Tanaka, Naomi Kitamoto
-
Publication number: 20170066737Abstract: The present invention provides compounds having a Toll-like receptor 4 (TLR4) signaling inhibitory action useful as preventive and therapeutic drugs of inflammatory disease and/or central nervous system disease or diseases such as chemotherapy-induced peripheral neuropathy (CIPN), chemotherapy-induced neuropathic pain (CINP), liver injury, ischemia-reperfusion injury (IRI) and the like. The present invention relates to a compound represented by formula (I) and a salt thereof: wherein, each symbol is explained in greater detail in the specification.Type: ApplicationFiled: November 21, 2016Publication date: March 9, 2017Applicant: Takeda Pharmaceutical Company LimitedInventors: Toshitake Kobayashi, Morihisa SAITOH, Yasufumi WADA, Hiroshi NARA, Nobuyuki NEGORO, Taisuke KATOH, Masashi YAMASAKI, Takahiro TANAKA, Naomi KITAMOTO
-
Publication number: 20160326102Abstract: The present invention provides compounds having a Toll-like receptor 4 (TLR4) signaling inhibitory action useful as preventive and therapeutic drugs of inflammatory disease and/or central nervous system disease or diseases such as chemotherapy-induced peripheral neuropathy (CIPN), chemotherapy-induced neuropathic pain (CINP), liver injury, ischemia-reperfusion injury (IRI) and the like. The present invention relates to a compound represented by formula (I) and a salt thereof: (wherein, each symbol is explained in greater detail in the specification).Type: ApplicationFiled: May 6, 2016Publication date: November 10, 2016Applicant: Takeda Pharmaceutical Company LimitedInventors: Toshitake Kobayashi, Morihisa SAITOH, Yasufumi WADA, Hiroshi NARA, Nobuyuki NEGORO, Taisuke KATOH, Masashi YAMASAKI, Takahiro TANAKA, Naomi KITAMOTO
-
Publication number: 20160326133Abstract: The present invention provides compounds having a Toll-like receptor 4 (TLR4) signaling inhibitory action useful as preventive and therapeutic drugs of inflammatory disease and/or central nervous system disease or diseases such as chemotherapy-induced peripheral neuropathy (CIPN), chemotherapy-induced neuropathic pain (CINP), liver injury, ischemia-reperfusion injury (IRI) and the like. The present invention relates to a compound represented by formula (I) and a salt thereof: (wherein, each symbol is explained in greater detail in the specification).Type: ApplicationFiled: June 7, 2016Publication date: November 10, 2016Applicant: Takeda Pharmaceutical Company LimitedInventors: Toshitake Kobayashi, Morihisa SAITOH, Yasufumi WADA, Hiroshi NARA, Nobuyuki NEGORO, Taisuke KATOH, Masashi YAMASAKI, Takahiro TANAKA, Naomi KITAMOTO
-
Publication number: 20160166526Abstract: The present invention provides a medicament that suppresses (or mitigates) various neurological symptoms caused by a peripheral nerve disorder induced by an anti-cancer agent.Type: ApplicationFiled: February 19, 2016Publication date: June 16, 2016Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventor: NAOMI KITAMOTO
-
Publication number: 20150203464Abstract: The present invention provides a medicament that suppresses (or mitigates) various neurological symptoms caused by a peripheral nerve disorder induced by an anti-cancer agent.Type: ApplicationFiled: April 2, 2015Publication date: July 23, 2015Applicant: Takeda Pharmaceutical Company LimitedInventor: Naomi Kitamoto
-
Publication number: 20150051256Abstract: The present invention provides a medicament that suppresses (or mitigates) various neurological symptoms caused by a peripheral nerve disorder induced by an anti-cancer agent.Type: ApplicationFiled: October 28, 2014Publication date: February 19, 2015Applicant: Takeda Pharmaceutical Company LimitedInventor: Naomi Kitamoto
-
Patent number: 8901171Abstract: The present invention provides a medicament that suppresses (or mitigates) various neurological symptoms caused by a peripheral nerve disorder induced by an anti-cancer agent.Type: GrantFiled: August 20, 2013Date of Patent: December 2, 2014Assignee: Takeda Pharmaceutical Company LimitedInventor: Naomi Kitamoto
-
Publication number: 20130345304Abstract: The present invention provides a medicament that suppresses (or mitigates) various neurological symptoms caused by a peripheral nerve disorder induced by an anti-cancer agent.Type: ApplicationFiled: August 20, 2013Publication date: December 26, 2013Applicant: Takeda Pharmaceutical Company LimitedInventor: Naomi Kitamoto
-
Publication number: 20130046000Abstract: The present invention provides a medicament that suppresses (or mitigates) various neurological symptoms caused by a peripheral nerve disorder induced by an anti-cancer agent.Type: ApplicationFiled: January 26, 2011Publication date: February 21, 2013Inventor: Naomi Kitamoto